

Edgar Filing: CEL SCI CORP - Form 8-K

CEL SCI CORP  
Form 8-K  
February 13, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 8, 2017

CEL-SCI CORPORATION  
-----

(Exact name of Registrant as specified in its charter)

----- Colorado -----	----- 01-11889 -----	----- 84-0916344 -----
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

8229 Boone Boulevard, Suite 802  
Vienna, Virginia 22182  
-----

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (703) 506-9460

N/A  
-----

(Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-14(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

## Edgar Filing: CEL SCI CORP - Form 8-K

CEL-SCI met with FDA on February 8, 2017. At this meeting, there was a discussion of steps that would be required to lift the partial clinical hold. CEL-SCI has immediately begun working on those steps which, subject to the FDA's review of CEL-SCI's submission upon their completion, may or may not result in the lifting of the partial clinical hold.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 13, 2017

CEL-SCI CORPORATION

By: /s/ Patricia B. Prichep

-----  
Patricia B. Prichep  
Senior Vice President of Operations